News

The European Union's executive said that it has signed a contract with Gilead for its COVID-19 medicine remdesivir that would cover 30,000 patients in the bloc from early August. "The Commission signed a contract with the pharmaceutical company Gilead for...

AstraZeneca’s Calquence has been recommended for marketing authorisation in the EU for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The Committee for Medicinal Products for Human Use (CHMP) of...

Moderna has unveiled a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of...

LGM Pharma announced that it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. The combination brings together LGM Pharma’s global leadership in Active Pharmaceutical Ingredient (API) sourcing, distribution and supply chain management...

Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients. Samsung Biologics has been providing aseptic filling and lyophilization services...

LabCorp’s drug development business, Covance, has acquired GlobalCare, a provider of patient-centric decentralized clinical trials support services. This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. Covance will leverage GlobalCare’s mobile healthcare...

Avid Bioservices, Inc., a biologics CDMO, and Argonaut Manufacturing Services, a cGMP contract manufacturing organization (CMO) have entered a co-marketing agreement to provide an integrated manufacturing solution including process development, drug substance manufacturing, and drug product manufacturing. The companies...